NASDAQ:BMRA Biomerica (BMRA) Stock Price, News & Analysis $0.57 +0.00 (+0.02%) As of 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomerica Stock (NASDAQ:BMRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomerica alerts:Sign Up Key Stats Today's Range$0.56▼$0.5850-Day Range$0.44▼$1.0352-Week Range$0.24▼$1.27Volume101,653 shsAverage Volume2.20 million shsMarket Capitalization$10.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Read More… Remove Ads Biomerica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreBMRA MarketRank™: Biomerica scored higher than 16% of companies evaluated by MarketBeat, and ranked 868th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Biomerica. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomerica is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomerica is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomerica has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomerica's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.32% of the float of Biomerica has been sold short.Short Interest Ratio / Days to CoverBiomerica has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomerica has recently decreased by 65.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomerica does not currently pay a dividend.Dividend GrowthBiomerica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.32% of the float of Biomerica has been sold short.Short Interest Ratio / Days to CoverBiomerica has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomerica has recently decreased by 65.46%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.75 News SentimentBiomerica has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biomerica this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for BMRA on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomerica insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.28% of the stock of Biomerica is held by institutions.Read more about Biomerica's insider trading history. Receive BMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRA Stock News HeadlinesBiomerica, Inc. (NASDAQ:BMRA) Sees Significant Decrease in Short InterestMarch 27, 2025 | americanbankingnews.comBiomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative ColitisFebruary 26, 2025 | markets.businessinsider.com“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…April 2, 2025 | True Market Insiders (Ad)Biomerica achieves IVDR certification in European unionFebruary 26, 2025 | msn.comBiomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn's Disease and Ulcerative ColitisFebruary 26, 2025 | globenewswire.comBiomerica's inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical JournalFebruary 19, 2025 | globenewswire.comUnited Arab Emirates MOHAP approves Biomerica’s Fortel PSA Screening TestJanuary 16, 2025 | markets.businessinsider.comBiomerica's rapid PSA test gains UAE approvalJanuary 16, 2025 | msn.comSee More Headlines BMRA Stock Analysis - Frequently Asked Questions How have BMRA shares performed this year? Biomerica's stock was trading at $0.3001 at the start of the year. Since then, BMRA shares have increased by 89.6% and is now trading at $0.5689. View the best growth stocks for 2025 here. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) issued its earnings results on Tuesday, January, 14th. The company reported ($0.06) earnings per share (EPS) for the quarter. Biomerica had a negative trailing twelve-month return on equity of 90.19% and a negative net margin of 100.52%. How do I buy shares of Biomerica? Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings1/14/2025Today4/02/2025Next Earnings (Estimated)4/10/2025Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMRA CIK73290 Webwww.biomerica.com Phone(949) 645-2111Fax949-553-1231Employees60Year Founded1971Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,980,000.00 Net Margins-100.52% Pretax Margin-100.31% Return on Equity-90.19% Return on Assets-64.54% Debt Debt-to-Equity RatioN/A Current Ratio3.17 Quick Ratio2.22 Sales & Book Value Annual Sales$5.58 million Price / Sales1.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book1.46Miscellaneous Outstanding Shares18,337,000Free Float15,586,000Market Cap$10.45 million OptionableOptionable Beta-1.17 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:BMRA) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.